Jill Samis, MD; and Aviva B. Sopher, MD, MS, discuss how central precocious puberty involves early activation of the hypothalamic-pituitary-gonadal axis before age 8 in girls and age 9 in boys. This requires individualized treatment decisions based on factors such as growth velocity, bone age advancement, and psychosocial impact, with GnRH agonist therapies available in multiple formulations (injections and implants) that effectively suppress puberty while preserving final height potential and have reassuring long-term safety profiles for bone health and fertility outcomes.
